Argireline vs Palmitoyl Tripeptide-38
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Acetyl Hexapeptide-3, Acetyl Hexapeptide-8
Argireline is the trade name for acetyl hexapeptide-8 (sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, also called acetyl hexapeptide-3), a synthetic peptide sold in anti-aging creams as a topical, needle-free alternative to Botox. It is designed to relax the muscle contractions behind expression lines. It is a cosmetic ingredient, not an FDA-approved drug, and the human efficacy data are genuinely mixed rather than settled.
Also: Matrixyl synthe'6, Matrixyl Synthe 6
Palmitoyl tripeptide-38 is the active in Sederma's Matrixyl synthe'6, a newer member of the Matrixyl family launched around 2011. It is a three-amino-acid fragment with a fatty acid tail, sold as a wrinkle 'filler from the inside' for forehead lines and crow's feet. It is a cosmetic ingredient, not a drug, and the honest picture is simple: the efficacy claims come almost entirely from the company that makes it.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Argireline | Palmitoyl Tripeptide-38 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Argireline is a fragment that copies the N-terminal end of SNAP-25, a protein nerve endings rely on to release acetylcholine and trigger muscle contraction. By competing for a place in the SNARE complex that powers that release, it is meant to blunt the muscle firing that folds skin into wrinkles, the same target Botox hits, but reversibly and far more weakly. The original lab work showed it really can inhibit neurotransmitter release in cell systems. The unresolved question is whether a topical cream delivers enough peptide deep enough to affect actual facial muscle, since the molecule is water-loving and does not cross the skin barrier easily. | The peptide is Pal-Lys-Met(O2)-Lys: lysine, an oxidized methionine (methionine sulfone) and lysine, with a palmitic acid chain attached so it can get into the outer skin more easily. The sequence is taken from connective tissue proteins (collagen VI and laminin), and the idea is the classic 'matrikine' story: small fragments of broken-down matrix proteins act as a signal telling skin cells to make more matrix. Sederma claims it boosts six components in lab tests, which is where the 'synthe'6' name comes from: collagen I, III and IV, fibronectin, hyaluronic acid and laminin-5. That is a plausible signaling mechanism, but it rests on cell culture work by the manufacturer. Whether enough peptide reaches the dermis in real skin to make a measurable difference has not been independently shown. |
| Common Dosing | Limited community data available See research protocols | 2% of the commercial ingredient in a finished product Once or twice daily |
| Administration | Topical (serums, creams) | Topical (serums, creams) |
| Typical Duration | Ongoing use for maintained effects | About 2 months in the manufacturer's study before changes were measured; ongoing use to keep any effect |
| Best Time to Take | Morning and evening (topical) | Morning and/or evening, on clean skin before moisturizer |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The headline 30 percent wrinkle-depth reduction comes from the 2002 Blanes-Mira study, which used a 10 percent peptide oil-in-water emulsion and confirmed the SNARE-interference mechanism in cell assays. That study is the foundation of nearly every marketing claim since. But independent human work is far less flattering: a double-blind split-face trial using VISIA imaging on 19 women found that four weeks of an Argireline serum produced no statistically significant wrinkle improvement over the placebo side, and the authors concluded it is not a substitute for botulinum toxin. A 2025 review found penetration studies in direct conflict, with one reporting around 30 percent stratum-corneum passage and another only about 0.2 percent, and noted that no in vivo study actually demonstrated the muscle-inhibition mechanism it is sold on. Bottom line: real cosmetic peptide, plausible science, but the strongest positive data are old and largely tied to its developers, while better-controlled independent trials are small and underwhelming. Safety is reassuring, with no serious adverse effects reported. | There is no independent, peer-reviewed clinical trial of palmitoyl tripeptide-38 on its own that we could find. The main human data is the manufacturer's: a placebo-controlled study in 25 women aged 42 to 70 with forehead lines and crow's feet, using 2% of the Matrixyl synthe'6 ingredient for two months, with reported reductions in wrinkle measures that ranged widely between people. Sederma's launch material in 2011 described visibly smoother forehead and crow's feet wrinkles after two months but gave no published sample sizes or numbers. Where the peptide shows up in published journals, it is usually as one ingredient in a multi-ingredient serum, which cannot isolate its effect. Broader reviews of cosmetic peptides make the same point about this whole category: results are often small, short and unpublished outside company brochures. A 2026 meta-analysis of randomized peptide trials found that topical peptides overall did not produce a significant wrinkle improvement in pooled data. Bottom line: a reasonable, well-tolerated ingredient with a plausible mechanism, but expect mild changes at best and treat the percentage claims as marketing until someone outside the company repeats them. |
Frequently Asked Questions: Argireline vs Palmitoyl Tripeptide-38
What is the difference between Argireline and Palmitoyl Tripeptide-38?
Argireline is a skin & hair peptide that argireline is the trade name for acetyl hexapeptide-8 (sequence ac-glu-glu-met-gln-arg-arg-nh2, also called acetyl hexapeptide-3), a synthetic peptide sold in anti-aging creams as a topical, needle-free alternative to botox. it is designed to relax the muscle contractions behind expression lines. it is a cosmetic ingredient, not an fda-approved drug, and the human efficacy data are genuinely mixed rather than settled. Palmitoyl Tripeptide-38 is a skin & hair peptide that palmitoyl tripeptide-38 is the active in sederma's matrixyl synthe'6, a newer member of the matrixyl family launched around 2011. it is a three-amino-acid fragment with a fatty acid tail, sold as a wrinkle 'filler from the inside' for forehead lines and crow's feet. it is a cosmetic ingredient, not a drug, and the honest picture is simple: the efficacy claims come almost entirely from the company that makes it. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Argireline or Palmitoyl Tripeptide-38?
Neither is universally "better" - the choice depends on your specific goals. Argireline is typically used for skin & hair purposes, while Palmitoyl Tripeptide-38 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Argireline and Palmitoyl Tripeptide-38 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Argireline and Palmitoyl Tripeptide-38 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.